Department of Gastroenterology and Hepatology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.
Gastroenterology. 2024 Sep;167(4):788-797.e2. doi: 10.1053/j.gastro.2024.04.028. Epub 2024 Apr 30.
BACKGROUND & AIMS: In more than half of the colorectal cancer screening participants with a positive fecal immunochemical test (FIT) result, no advanced neoplasia (AN) is detected at colonoscopy. The positive FIT result could also be generated by cancers located proximal to the colon: upper gastrointestinal, oral cavity, nose, and throat cancers. We evaluated screenees' risk of being diagnosed with a cancer proximal to the colon within the 3 years and compared risks between those with a positive vs those with a negative FIT.
Data of Dutch colorectal cancer screening participants who underwent biennial FIT-based screening 2014-2018 were collected from the national screening database and linked to the National Cancer Registry. Screenees were classified into 3 groups: FIT-positives with AN (FIT+/AN+), FIT-positives without AN (FIT+/AN-), and FIT-negatives (FIT-). We compared the cumulative incidence of cancers proximal to the colon in each group 3 years after FIT. A Cox regression analysis with left truncation and right censoring, using FIT positivity as time-dependent variable and stratified for sex, was performed to compare the hazard of cancers proximal to the colon in participants who were FIT-positive vs FIT-negative.
Three-year cumulative incidence of cancers proximal to the colon in FIT+/AN+ (n = 65,767), FIT+/AN- (n = 50,661), and FIT- (n = 1,831,647) screenees was 0.7%, 0.6%, and 0.4%, respectively (P < .001). FIT-positives were older and more frequently male than FIT-negatives (P < .001). Significantly more cancers proximal to the colon were detected among FIT-positives (P < .001; hazard ratio, 1.55; 95% CI, 1.44-1.67).
FIT-positive screenees were at significantly increased risk of being diagnosed with a cancer proximal to the colon within 3 years after FIT, although the 3-year cumulative incidence was still less than 1%.
在半数以上接受粪便免疫化学检测(FIT)阳性的结直肠癌筛查参与者中,结肠镜检查未发现高级别肿瘤(AN)。阳性 FIT 结果也可能由结肠近端的癌症产生:上消化道、口腔、鼻腔和咽喉癌。我们评估了筛查者在 3 年内被诊断为结肠近端癌症的风险,并比较了阳性 FIT 与阴性 FIT 者之间的风险。
从国家筛查数据库中收集了 2014-2018 年接受每两年一次基于 FIT 的筛查的荷兰结直肠癌筛查参与者的数据,并将其与国家癌症登记处相关联。筛查者分为三组:FIT 阳性伴 AN(FIT+/AN+)、FIT 阳性不伴 AN(FIT+/AN-)和 FIT 阴性(FIT-)。我们比较了每组 FIT 后 3 年结肠近端癌症的累积发病率。使用 FIT 阳性作为时依变量、性别分层的左截断和右删失的 Cox 回归分析,比较了 FIT 阳性与 FIT 阴性参与者结肠近端癌症的风险。
FIT+/AN+(n=65767)、FIT+/AN-(n=50661)和 FIT-(n=1831647)筛查者 3 年累积结肠近端癌症发病率分别为 0.7%、0.6%和 0.4%(P<0.001)。FIT 阳性者比 FIT 阴性者年龄更大,且更常为男性(P<0.001)。FIT 阳性者中明显更多的结肠近端癌症被检出(P<0.001;危险比,1.55;95%CI,1.44-1.67)。
尽管 3 年累积发病率仍低于 1%,但 FIT 阳性筛查者在 FIT 后 3 年内被诊断为结肠近端癌症的风险显著增加。